Setting New Therapeutic Standards in Advanced HCC

Download this slideset for expert perspectives on best practices and emerging strategies in using immune checkpoint inhibitor combinations for patients with advanced hepatocellular carcinoma.
Richard S. Finn, MD
Amit G. Singal, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 3.61 MB
Released: November 12, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Related Content

Phase I/II ReFocus: RLY-4008 in patients with FGFR inhibitor-naive cholangiocarcinoma with FGFR2 alterations, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

Downloadable slideset on the role of biomarker testing and practical information on the use of targeted therapies in NSCLC for oncology nurses, from Clinical Care Options (CCO).

person default Beth Sandy, MSN, CRNP Elizabeth S. Waxman, BSN, MSN, ANP-BC Released: September 20, 2022

From Clinical Care Options (CCO), download slides reviewing contemporary systemic therapy for HCC and BTC

James M. Cleary, MD, PhD Mark Yarchoan, MD Released: September 19, 2022

Primary results from phase III LEAP-002 study of lenvatinib with or without pembrolizumab as first-line treatment for patients with advanced hepatocellular carcinoma, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings